Begin patient enrollment in a third cohort of the AMT-130 study
Not delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 28 Feb 2022
- Due
- 31 Dec 2022
- Checked
- 1 Oct 2026
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Patient enrollment in a third cohort is expected to begin in the second half of 2022”
What we found
Evidence strength A What the grades mean
The company did not begin enrollment for the third cohort in 2022; a later filing indicates the third cohort was expected to start enrolling in the fourth quarter of 2023.
-
A uniQure N.V. 10-Q filed 2023-11-07
“Two remaining patients initially scheduled for the EU open-label study will now be enrolled in Cohort 3, which is expected to start enrolling in the fourth quarter of 2023” ✓ confirmed on the page
Market reaction: the shares moved +2.7% against the S&P 500 over the three sessions around the disclosure (6 Nov 2023 to 9 Nov 2023). What this measures
Checked 1 Oct 2026.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- Deadline drift +731 days
- 4 versions
-
Version 1 · original · stated 28 Feb 2022
Deadline 31 Dec 2022 (“in the second half of 2022”) · wording expected
-
Version 2 · stated 2 May 2022
Deadline 31 Dec 2022 (“second half of 2022”) · target 18 patients · wording expected
“A third cohort exploring the use of an alternative stereotactic navigation system to simplify placement of infusion catheters in up to 18 additional randomized patients is expected to commence enrollment in the second half of”
-
Version 3 · stated 27 Feb 2023
Deadline 31 Dec 2023 (“in the second half of 2023”) · wording expected
“A third cohort of patients is expected to begin enrollment in the U.S. in the second half of 2023”
-
Version 4 · stated 28 Feb 2024
Deadline 31 Dec 2024 (“second half of 2024”) · wording expected
“Enrollment in this cohort is expected to be completed in the second half of 2024.”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Begin
- Deliverable
- patient enrollment
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
- Third check on a negative finding: agreesBecause a negative finding could harm a company if wrong, a stronger model re-read the evidence fully blind and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you uniQure N.V.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2022-QURE-001796 · Corrections policy